Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 12
Submit an article Journal homepage
835
Views
12
CrossRef citations to date
0
Altmetric
Original Article: Clinical

DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma

Hiu Lam Agnes YuenDepartment of Clinical Haematology, Alfred Health, Melbourne, Australia; ;Monash Haematology, Monash Health, Melbourne, Australia; ORCID Iconhttp://orcid.org/0000-0001-8349-6782
ORCID Icon,
Michael Sze Yuan LowMonash Haematology, Monash Health, Melbourne, Australia; ;Hudson Institute of Medical Research and Southern Clinical School, Monash University, Clayton, Australia;
,
Pasquale FedeleMonash Haematology, Monash Health, Melbourne, Australia; ;Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, Australia;
,
Anna KalffDepartment of Clinical Haematology, Alfred Health, Melbourne, Australia;
,
Patricia WalkerDepartment of Clinical Haematology, Alfred Health, Melbourne, Australia;
,
Krystal BerginDepartment of Clinical Haematology, Alfred Health, Melbourne, Australia;
,
John CoutsouvelisCentre for Medicine Use and Safety, Monash University, Clayton, Australia; ;Pharmacy Department, Alfred Health, Melbourne, Australia;
,
George GrigoriadisDepartment of Clinical Haematology, Alfred Health, Melbourne, Australia; ;Monash Haematology, Monash Health, Melbourne, Australia; ;Hudson Institute of Medical Research and Southern Clinical School, Monash University, Clayton, Australia; Correspondence[email protected]
&
Andrew SpencerDepartment of Clinical Haematology, Alfred Health, Melbourne, Australia; ;Australian Centre for Blood Diseases, Monash University, Melbourne, AustraliaCorrespondence[email protected]
 show all
Pages 2842-2846 | Received 10 Dec 2017, Accepted 13 Mar 2018, Published online: 04 Apr 2018

References

  • Australian Institute of Health and Welfare. Cancer in Australia: an overview; 2014.
  • Corso A, Arcaini L, Caberlon S, et al. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica. 2002;87:1041–1045.
  • Lazzarino M, Corso A, Barbarano L, et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant. 2001;28:835–839.
  • Munshi ND, Jagannath S. Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP): an effective regimen for relapse after high-dose chemotherapy and autologous transplantation. Blood. 1996;88(1):586a.
  • Quach H, Prince M, MSAG [Internet]. Clinical practice guideline: multiple myeloma 2012 [updated December 2012; cited 2015 Jul 4]. Available from: http://myeloma.org.au/resources/MSAG_guidlines_v%202%20update%20-due%20Dec%2014.pdf
  • Griffin PT, Ho VQ, Fulp W, et al. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer. 2015;121:3622–3630.
  • Park S, Lee SJ, Jung CW, et al. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. Ann Hematol. 2014;93:99–105.
  • Valla K, Kaufman JL, Gleason C, et al. editors. Bortezomib in combination with dexamethasone, cyclophosphamide, etoposide, and cisplatin (V-DCEP) for the treatment of multiple myeloma. 56th ASH Annual Meeting and Exposition; 2014; San Francisco, CA.
  • Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–4695.
  • Dadacaridou M, Papanicolaou X, Maltesas D, et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON. 2007;12:41–44.
  • Gerrie AS, Mikhael JR, Cheng L, et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol. 2013;161:802–810.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.